Identification of anti-<i>Helicobacter pylori</i> antibody signatures in gastric intestinal metaplasia

Simple item page
dc.contributor.authorSong, Lusheng
dc.contributor.authorSong, Minkyo
dc.contributor.authorRabkin, Charles S.
dc.contributor.authorChung, Yunro
dc.contributor.authorWilliams, Stacy
dc.contributor.authorTorres, Javier
dc.contributor.authorCorvalan, Alejandro H.
dc.contributor.authorGonzalez, Robinson
dc.contributor.authorBellolio, Enrique
dc.contributor.authorShome, Mahasish
dc.contributor.authorLaBaer, Joshua
dc.contributor.authorQiu, Ji
dc.contributor.authorCamargo, M. Constanza
dc.date.accessioned2025-01-20T20:20:37Z
dc.date.available2025-01-20T20:20:37Z
dc.date.issued2023
dc.description.abstractBackground Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. Methods We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with >= 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). Results Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tip alpha [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tip alpha [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). Conclusions Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance.
dc.fuente.origenWOS
dc.identifier.doi10.1007/s00535-022-01933-0
dc.identifier.eissn1435-5922
dc.identifier.issn0944-1174
dc.identifier.urihttps://doi.org/10.1007/s00535-022-01933-0
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92587
dc.identifier.wosidWOS:000874428700002
dc.issue.numero2
dc.language.isoen
dc.pagina.final124
dc.pagina.inicio112
dc.revistaJournal of gastroenterology
dc.rightsacceso restringido
dc.subjectIntestinal metaplasia
dc.subjectH
dc.subjectpylori
dc.subjectNAPPA
dc.subjectSerology
dc.subjectPremalignant lesions
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleIdentification of anti-<i>Helicobacter pylori</i> antibody signatures in gastric intestinal metaplasia
dc.typeartículo
dc.volumen58
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas